BBOT Posts $56.5M Q2 Loss, Extends Cash Runway into 2028, and Advances KRAS Pipeline
BBOT sits 31% above its 52-week low of $7.
Summary
BBOT's Q2 loss widened to $56.5M on higher R&D spending, but $344.1M in cash provides runway into 2028. Clinical progress includes new combination dosing for its KRAS inhibitors.
Key Events · Earnings and Guidance · BBOT
-
Q2 Net Loss Widens to $56.5M
Net loss of $56.5M vs. $28.4M in Q2 2025, driven by R&D expenses of $49.2M (up from $27.4M) and G&A of $11.0M (up from $2.7M).
-
Cash Runway Extended into 2028
Cash, equivalents, and marketable securities totaled $344.1M at June 30, 2026, expected to fund operations into 2028.
-
Clinical Pipeline Advances
Initiated BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combinations; continued enrollment in BBO-8520 + pembrolizumab and BBO-8520 + BBO-10203 cohorts.
-
Preclinical Data Presented at AACR
Data highlighted BBO-11818 potency in KRAS G12D/V models and BBO-10203 efficacy in combination with HER2 inhibitors in HER2amp models.
Analysis · BBOT · Life Sciences
BridgeBio Oncology Therapeutics posted a wider Q2 loss of $56.5 million, driven by a near-doubling of R&D spend to $49.2 million as it advances three clinical-stage KRAS/PI3Kα programs. The company initiated two new combination cohorts — BBO-11818 with cetuximab and with BBO-10203 — and presented preclinical data at AACR. With $344.1 million in cash, management expects runway into 2028, removing near-term financing risk. The burn rate is high, but the pipeline progress and extended cash horizon are the key takeaways.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBOT was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737M. The 52-week trading range was $7.00 to $14.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.